<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03919981</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL18_0685</org_study_id>
    <secondary_id>2019-A00166-51</secondary_id>
    <nct_id>NCT03919981</nct_id>
  </id_info>
  <brief_title>CYSTEA-BONE Clinical Study</brief_title>
  <acronym>CYSTEA-BONE</acronym>
  <official_title>A European, Multicenter, Prospective Clinical Study to Evaluate Cysteamine Toxicity on Human Osteoclasts. The CYSTEA-BONE Clinical Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nephropathic Cystinosis (NC) is an orphan inherited autosomal recessive disease characterised
      as a generalized lysosomal storage disease due to a deficiency of the cystine lysosomal
      transport protein, cystinosin.

      Patients with NC usually receive cysteamine. Bone impairment was recently recognized as a
      late complication of NC, occurring at adolescence or early adulthood. Even though the exact
      underlying pathophysiology is unclear, at least six hypotheses are discussed, and mainly
      cysteamine toxicity and/or direct bone effect of the Cystinosin (CTNS) mutation. Because of
      the potential dramatic impact on quality of life of this novel complication, research should
      aim to better understand bone disease in NC.

      The primary objective of this study is to evaluate the action of cysteamine on osteoclastic
      differentiation and resorption activity of NC patients, depending on the underlying genotype.
      The Secondary objective is to describe the clinical bone status of NC patients depending on
      their underlying genotype.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2019</start_date>
  <completion_date type="Anticipated">October 5, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 5, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of positive Tartrate-resistant acid phosphatase (TRAP) cells</measure>
    <time_frame>1 day</time_frame>
    <description>Number of positive TRAP cells will be assessed at the end of osteoclast differentiation from circulating monocytes</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Nephropathic Cystinosis</condition>
  <arm_group>
    <arm_group_label>nephropathic cystinosis patients receiving cysteamine</arm_group_label>
    <description>nephropathic cystinosis patients receiving cysteamine. The blood samples of the group will be used to evaluate the action of cysteamine on osteoclastic differentiation and resorption activity of NC patients, depending on the underlying genotype.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>25 mL blood sample will be collected on citrate tubes for osteoclastic analysis.</description>
    <arm_group_label>nephropathic cystinosis patients receiving cysteamine</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      25 mL blood sample will be collected on citrate tubes for osteoclastic analysis.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with nephropathic cystinosis (NC)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects with confirmed diagnosis of nephropathic cystinosis (defined
             by clinical signs, White Blood Cells (WBC) cystine level and/or mutation), currently
             receiving oral cysteamine.

          -  Age &gt; 2 years.

          -  Subjects and/or their parents/ legal guardian must provide non opposition prior to
             participation in the study.

        Exclusion Criteria:

          -  Subjects who, in the opinion of the Investigator, are not able or willing to comply
             with the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Justine BACCHETTA, MD PhD</last_name>
    <phone>04 27 85 61 30</phone>
    <phone_ext>+33</phone_ext>
    <email>justine.bacchetta@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Segolene GAILLARD</last_name>
    <phone>04 27 85 77 28</phone>
    <phone_ext>+33</phone_ext>
    <email>segolene.gaillard@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francois NOBILI, MD,PhD</last_name>
      <phone>03 81 21 88 15</phone>
      <phone_ext>+33</phone_ext>
      <email>fnobili@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Francois NOBILI, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux - Hôpital Pellegrin tripode</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérome HARAMBAT, PU PH</last_name>
      <phone>05 56 79 56 79</phone>
      <phone_ext>+33</phone_ext>
      <email>jérome.harambat@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Jérome HARAMBAT, PU PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Femme Mère Enfant</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justine BACCHETTA, PU PH</last_name>
      <phone>04 27 85 61 30</phone>
      <phone_ext>+33</phone_ext>
      <email>justine.bacchetta@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Segolene GAILLARD</last_name>
      <phone>04 27 85 77 28</phone>
      <phone_ext>+33</phone_ext>
      <email>segolene.gaillard@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Justine BACCHETTA, PU PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Jeanne de Flandre</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert NOVO, MD PHD</last_name>
      <phone>03 20 44 46 95</phone>
      <phone_ext>+33</phone_ext>
      <email>robert.novo@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Robert NOVO, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine LEMOINE, PhD</last_name>
      <phone>04 72 11 02 44</phone>
      <phone_ext>+33</phone_ext>
      <email>sandrine.lemoine01@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Laurence DUBOURG, PhD</last_name>
      <phone>04 72 11 02 44</phone>
      <phone_ext>+33</phone_ext>
      <email>laurence.dubourg@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Sandrine LEMOINE, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurence DUBOURG, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HM - Timone Enfants</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline ROUSSET-ROUVIERE, MD PHD</last_name>
      <phone>04 91 38 80 50</phone>
      <phone_ext>+33</phone_ext>
      <email>caroline.rousset-rouviere@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Caroline ROUSSET-ROUVIERE, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Paris - Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georges DESCHENES, PU PH</last_name>
      <phone>01 40 03 24 67</phone>
      <phone_ext>+33</phone_ext>
      <email>georges.deschenes@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Georges DESCHENES, PU PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Paris - Hôpital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aude SERVAIS, PU PH</last_name>
      <phone>01 44 49 54 16</phone>
      <phone_ext>+33</phone_ext>
      <email>aude.servais@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Olivia BOYER, MD PHD</last_name>
      <phone>01 44 49 54 16</phone>
      <phone_ext>+33</phone_ext>
      <email>olivia.boyer@aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Aude SERVAIS, PU PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivia BOYER, MD PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital des Enfants</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane DECRAMER, PU, PH</last_name>
      <phone>05 34 55 84 58</phone>
      <phone_ext>+33</phone_ext>
      <email>rdecramer.s@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane DECRAMER, PU, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy - Hôpital Brabois Enfants</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario PONGAS, MD PHD</last_name>
      <phone>03 83 15 47 41</phone>
      <phone_ext>+33</phone_ext>
      <email>a.pongas@outlook.com</email>
    </contact>
    <investigator>
      <last_name>Mario PONGAS, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Pädiatrische Nieren-, Leber- und Stoffwechselerkrankungen</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dieter HAFFNER, PU PH</last_name>
      <phone>511 532 3220</phone>
      <phone_ext>+49</phone_ext>
      <email>haffner.dieter@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Dieter HAFFNER, PU PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Pediatrico Bambino Gesù</name>
      <address>
        <city>Roma</city>
        <zip>00146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcella GRECO, MD PHD</last_name>
      <phone>06 68592393</phone>
      <phone_ext>+39</phone_ext>
      <email>marcella.greco@opbg.net</email>
    </contact>
    <contact_backup>
      <last_name>Francesco EMMA, PU PH</last_name>
      <phone>06 68592393</phone>
      <phone_ext>+39</phone_ext>
      <email>francesco.emma@opbg.net</email>
    </contact_backup>
    <investigator>
      <last_name>Marcella GRECO, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco EMMA, PU PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hacettepe University Faculty of Medicine</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rezan TOPALOGLU, PU PH</last_name>
      <phone>312 3051863</phone>
      <phone_ext>+90</phone_ext>
      <email>rezantopaloglu@hacettepe.edu.tr</email>
    </contact>
    <investigator>
      <last_name>Rezan TOPALOGLU, PU PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>April 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2019</study_first_posted>
  <last_update_submitted>November 13, 2019</last_update_submitted>
  <last_update_submitted_qc>November 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fanconi Syndrome</mesh_term>
    <mesh_term>Cystinosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

